Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
329 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dyslipidemia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H2 2015', provides an overview of the Dyslipidemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dyslipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dyslipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Dyslipidemia Overview 12 Therapeutics Development 13 Pipeline Products for Dyslipidemia - Overview 13 Pipeline Products for Dyslipidemia - Comparative Analysis 14 Dyslipidemia - Therapeutics under Development by Companies 15 Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 21 Dyslipidemia - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Dyslipidemia - Products under Development by Companies 26 Dyslipidemia - Products under Investigation by Universities/Institutes 34 Dyslipidemia - Companies Involved in Therapeutics Development 35 Acasti Pharma Inc. 35 Allergan Plc 36 Alnylam Pharmaceuticals, Inc. 37 Amgen Inc. 38 Arbutus Biopharma Corporation 39 Arisaph Pharmaceuticals, Inc. 40 Astellas Pharma Inc. 41 AstraZeneca Plc 42 AtheroNova Inc. 43 BASF SE 44 BCWorld Pharm Co. Ltd. 45 Cadila Pharmaceuticals Ltd. 46 Cardax Pharmaceuticals, Inc. 47 Catabasis Pharmaceuticals, Inc. 48 Cerenis Therapeutics Holding SA 49 Chong Kun Dang Pharmaceutical Corp. 50 CJ HealthCare Corp. 51 Connexios Life Sciences Pvt. Ltd. 52 CymaBay Therapeutics, Inc. 53 Daewoong Pharmaceutical Co., Ltd. 54 Daiichi Sankyo Company, Limited 55 Debiopharm International S.A. 56 Eli Lilly and Company 57 Gemphire Therapeutics Inc. 58 Genfit SA 59 GlaxoSmithKline Plc 60 HanAll Biopharma Co., Ltd. 61 Hanmi Pharmaceuticals, Co. Ltd. 62 Huons Co., Ltd. 63 Hyundai Pharmaceutical Co., Ltd. 64 Innovent Biologics, Inc. 65 IPCA Laboratories Limited 66 Isis Pharmaceuticals, Inc. 67 Jeil Pharmaceutical Co., Ltd. 68 Jenrin Discovery, Inc. 69 JW Pharmaceutical Corporation 70 Kissei Pharmaceutical Co., Ltd. 71 Kotobuki Pharmaceutical Co., Ltd. 72 Kowa Company, Ltd. 73 Kymab Limited 74 LG Life Science LTD. 75 Lipicard Technologies Limited 76 Lotus Pharmaceutical Co., Ltd. 77 Merck & Co., Inc. 78 Nimbus Therapeutics, LLC 79 Nippon Chemiphar Co., Ltd. 80 Pfizer Inc. 81 Pharmena SA 82 Prometheon Pharma, LLC 83 Protalix BioTherapeutics, Inc. 84 Sancilio & Company, Inc. 85 Takeda Pharmaceutical Company Limited 86 Thetis Pharmaceuticals LLC 87 Torrent Pharmaceuticals Limited 88 Viking Therapeutics, Inc. 89 Yuhan Corporation 90 Zydus Cadila Healthcare Limited 91 Dyslipidemia - Therapeutics Assessment 92 Assessment by Monotherapy Products 92 Assessment by Combination Products 93 Assessment by Target 94 Assessment by Mechanism of Action 99 Assessment by Route of Administration 102 Assessment by Molecule Type 104 Drug Profiles 106 (amlodipine besylate + atorvastatin + valsartan) - Drug Profile 106 (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 107 (atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 108 (atorvastatin calcium + losartan potassium) - Drug Profile 109 (atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 110 (candesartan + rosuvastatin calcium) - Drug Profile 111 (ezetimibe + rosuvastatin calcium) - Drug Profile 112 (gemigliptin + rosuvastatin calcium) - Drug Profile 113 (pitavastatin + valsartan) - Drug Profile 114 (rosuvastatin calcium + metformin SR) - Drug Profile 115 4655-K09 - Drug Profile 116 AEM-28 - Drug Profile 117 AEM-2802 - Drug Profile 118 AEM-2814 - Drug Profile 119 AHRO-001 - Drug Profile 120 ALN-AC3 - Drug Profile 122 ALN-ANG - Drug Profile 123 AMG-899 - Drug Profile 124 anacetrapib - Drug Profile 125 ARI-3037MO - Drug Profile 127 AS-1708727 - Drug Profile 128 AZ-12260493 - Drug Profile 129 BCWPC-001 - Drug Profile 130 bezafibrate ER - Drug Profile 131 BH-03004 - Drug Profile 132 BioE-1115 - Drug Profile 133 bococizumab - Drug Profile 134 BSN-272 - Drug Profile 135 C-24 - Drug Profile 136 C-3 - Drug Profile 137 CAT-2000 Series - Drug Profile 138 CAT-2003 - Drug Profile 139 CDR-267F018 - Drug Profile 140 CDX-085 - Drug Profile 141 centatin - Drug Profile 143 CER-209 - Drug Profile 144 CKD-519 - Drug Profile 145 CNX-013B2 - Drug Profile 146 Debio-0930B - Drug Profile 147 DF-461 - Drug Profile 148 DGAT-1 - Drug Profile 149 DPR-212 - Drug Profile 150 DS-8312 - Drug Profile 151 DWJ-1330 - Drug Profile 152 DWJ-1351 - Drug Profile 153 elafibranor - Drug Profile 154 etanercept biosimilar - Drug Profile 157 evolocumab - Drug Profile 158 gemcabene calcium - Drug Profile 161 GSK-2041706 - Drug Profile 162 HCP-1105 - Drug Profile 163 HOB-071 - Drug Profile 164 HU-012 - Drug Profile 165 IBI-306 - Drug Profile 166 icosabutate - Drug Profile 167 ISIS-ANGPTL3LRx - Drug Profile 168 ISIS-ANGPTL3Rx - Drug Profile 169 ISIS-APOCIIILRx - Drug Profile 170 JD-2000 Series - Drug Profile 171 JD-5000 Series - Drug Profile 172 JD-5006 - Drug Profile 173 JD-6000 Series - Drug Profile 174 JLP-1302 - Drug Profile 175 JLP-1401 - Drug Profile 176 K-312 - Drug Profile 177 K-877 - Drug Profile 178 KT-6971 - Drug Profile 180 KTA-439 - Drug Profile 181 KY-1020 - Drug Profile 182 leucine + niacin - Drug Profile 183 LP-071 - Drug Profile 184 LT-5421 - Drug Profile 185 LT-5423 - Drug Profile 186 MAT-9001 - Drug Profile 187 MBX-8025 - Drug Profile 188 MGL-3196 - Drug Profile 190 NC-2400 - Drug Profile 191 ND-630 - Drug Profile 192 ND-654 - Drug Profile 193 NKPL-66 - Drug Profile 195 Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 197 omega-3-carboxylic acids - Drug Profile 198 peroxibrate - Drug Profile 200 PF-06427878 - Drug Profile 201 pitavastatin CR - Drug Profile 202 Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 203 Recombinant ApoE4 for Dyslipidemia - Drug Profile 204 SC-401 - Drug Profile 205 Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 206 Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes - Drug Profile 207 Small Molecule for Hyperlipidemia - Drug Profile 208 Small Molecule for Hypertriglyceridaemia - Drug Profile 209 Small Molecule for Hypertriglyceridemia - Drug Profile 210 Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 211 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 212 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 213 Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 214 Small Molecule to Antagonise Farnesoid X Receptor for Dyslipidemia - Drug Profile 215 Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 216 Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 217 Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 218 Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 219 SPX-100 - Drug Profile 220 SPX-8522876 - Drug Profile 221 Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 222 TKM-HTG - Drug Profile 224 TKMApoC-3 - Drug Profile 225 TP-101 - Drug Profile 226 TP-110 - Drug Profile 227 TRC-210258 - Drug Profile 229 TRIA-662 - Drug Profile 230 VK-0214 - Drug Profile 232 VK-2809 - Drug Profile 233 volanesorsen sodium - Drug Profile 235 YH-22189 - Drug Profile 237 ZLN-005 - Drug Profile 238 ZLN-024 - Drug Profile 239 ZYH-7 - Drug Profile 240 ZYT-1 - Drug Profile 241 Dyslipidemia - Recent Pipeline Updates 242 Dyslipidemia - Dormant Projects 291 Dyslipidemia - Discontinued Products 306 Dyslipidemia - Product Development Milestones 312 Featured News & Press Releases 312 Appendix 320 Methodology 320 Coverage 320 Secondary Research 320 Primary Research 320 Expert Panel Validation 320 Contact Us 320 Disclaimer 321
List of Tables
Number of Products under Development for Dyslipidemia, H2 2015 21 Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2015 22 Number of Products under Development by Companies, H2 2015 24 Number of Products under Development by Companies, H2 2015 (Contd..1) 25 Number of Products under Development by Companies, H2 2015 (Contd..2) 26 Number of Products under Development by Companies, H2 2015 (Contd..3) 27 Number of Products under Development by Companies, H2 2015 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H2 2015 29 Comparative Analysis by Late Stage Development, H2 2015 30 Comparative Analysis by Clinical Stage Development, H2 2015 31 Comparative Analysis by Early Stage Development, H2 2015 32 Comparative Analysis by Unknown Stage Development, H2 2015 33 Products under Development by Companies, H2 2015 34 Products under Development by Companies, H2 2015 (Contd..1) 35 Products under Development by Companies, H2 2015 (Contd..2) 36 Products under Development by Companies, H2 2015 (Contd..3) 37 Products under Development by Companies, H2 2015 (Contd..4) 38 Products under Development by Companies, H2 2015 (Contd..5) 39 Products under Development by Companies, H2 2015 (Contd..6) 40 Products under Development by Companies, H2 2015 (Contd..7) 41 Products under Investigation by Universities/Institutes, H2 2015 42 Dyslipidemia - Pipeline by Acasti Pharma Inc., H2 2015 43 Dyslipidemia - Pipeline by Allergan Plc, H2 2015 44 Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 45 Dyslipidemia - Pipeline by Amgen Inc., H2 2015 46 Dyslipidemia - Pipeline by Arbutus Biopharma Corporation, H2 2015 47 Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 48 Dyslipidemia - Pipeline by Astellas Pharma Inc., H2 2015 49 Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2015 50 Dyslipidemia - Pipeline by AtheroNova Inc., H2 2015 51 Dyslipidemia - Pipeline by BASF SE, H2 2015 52 Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2015 53 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H2 2015 54 Dyslipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 55 Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015 56 Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 57 Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 58 Dyslipidemia - Pipeline by CJ HealthCare Corp., H2 2015 59 Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015 60 Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2015 61 Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 62 Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 63 Dyslipidemia - Pipeline by Debiopharm International S.A., H2 2015 64 Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2015 65 Dyslipidemia - Pipeline by Gemphire Therapeutics Inc., H2 2015 66 Dyslipidemia - Pipeline by Genfit SA, H2 2015 67 Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2015 68 Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 69 Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 70 Dyslipidemia - Pipeline by Huons Co., Ltd., H2 2015 71 Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 72 Dyslipidemia - Pipeline by Innovent Biologics, Inc., H2 2015 73 Dyslipidemia - Pipeline by IPCA Laboratories Limited, H2 2015 74 Dyslipidemia - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 75 Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 76 Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2015 77 Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H2 2015 78 Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 79 Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2015 80 Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2015 81 Dyslipidemia - Pipeline by Kymab Limited, H2 2015 82 Dyslipidemia - Pipeline by LG Life Science LTD., H2 2015 83 Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2015 84 Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2015 85 Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2015 86 Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H2 2015 87 Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 88 Dyslipidemia - Pipeline by Pfizer Inc., H2 2015 89 Dyslipidemia - Pipeline by Pharmena SA, H2 2015 90 Dyslipidemia - Pipeline by Prometheon Pharma, LLC, H2 2015 91 Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2015 92 Dyslipidemia - Pipeline by Sancilio & Company, Inc., H2 2015 93 Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 94 Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2015 95 Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2015 96 Dyslipidemia - Pipeline by Viking Therapeutics, Inc., H2 2015 97 Dyslipidemia - Pipeline by Yuhan Corporation, H2 2015 98 Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 99 Assessment by Monotherapy Products, H2 2015 100 Assessment by Combination Products, H2 2015 101 Number of Products by Stage and Target, H2 2015 103 Number of Products by Stage and Mechanism of Action, H2 2015 108 Number of Products by Stage and Route of Administration, H2 2015 111 Number of Products by Stage and Molecule Type, H2 2015 113 Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2015 250 Dyslipidemia - Dormant Projects, H2 2015 299 Dyslipidemia - Dormant Projects (Contd..1), H2 2015 300 Dyslipidemia - Dormant Projects (Contd..2), H2 2015 301 Dyslipidemia - Dormant Projects (Contd..3), H2 2015 302 Dyslipidemia - Dormant Projects (Contd..4), H2 2015 303 Dyslipidemia - Dormant Projects (Contd..5), H2 2015 304 Dyslipidemia - Dormant Projects (Contd..6), H2 2015 305 Dyslipidemia - Dormant Projects (Contd..7), H2 2015 306 Dyslipidemia - Dormant Projects (Contd..8), H2 2015 307 Dyslipidemia - Dormant Projects (Contd..9), H2 2015 308 Dyslipidemia - Dormant Projects (Contd..10), H2 2015 309 Dyslipidemia - Dormant Projects (Contd..11), H2 2015 310 Dyslipidemia - Dormant Projects (Contd..12), H2 2015 311 Dyslipidemia - Dormant Projects (Contd..13), H2 2015 312 Dyslipidemia - Dormant Projects (Contd..14), H2 2015 313 Dyslipidemia - Discontinued Products, H2 2015 314 Dyslipidemia - Discontinued Products (Contd..1), H2 2015 315 Dyslipidemia - Discontinued Products (Contd..2), H2 2015 316 Dyslipidemia - Discontinued Products (Contd..3), H2 2015 317 Dyslipidemia - Discontinued Products (Contd..4), H2 2015 318 Dyslipidemia - Discontinued Products (Contd..5), H2 2015 319
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
